Study of IMP4297 in Patients With BRCA1/2 Mutation Ovarian Cancer (SABRINA)
A Phase II Study to Evaluate the Efficacy, Safety, and Tolerability of IMP4297 Capsules in Subjects With Germline and/or Somatic BRCA1/2 Mutation Positive Advanced Ovarian Cancer With at Least 2 Prior Lines of Standard Systemic Therapy
Sponsor: Impact Therapeutics, Inc.
This PHASE2 trial investigates Ovarian Cancer and is currently completed. Impact Therapeutics, Inc. leads this study, which shows 10 recorded versions since 2019 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
10 versions recorded-
Feb 2026 — Present [monthly]
Completed PHASE2
-
Oct 2025 — Feb 2026 [monthly]
Completed PHASE2
Status: Unknown → Completed
-
Sep 2024 — Oct 2025 [monthly]
Unknown PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE2
Status: Unknown Status → Unknown
-
Dec 2022 — Jul 2024 [monthly]
Unknown Status PHASE2
Status: Recruiting → Unknown Status
▶ Show 5 earlier versions
-
Jan 2021 — Dec 2022 [monthly]
Recruiting PHASE2
-
Dec 2020 — Jan 2021 [monthly]
Recruiting PHASE2
-
Mar 2020 — Dec 2020 [monthly]
Recruiting PHASE2
-
Dec 2019 — Mar 2020 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Oct 2019 — Dec 2019 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Impact Therapeutics, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .